Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1993 2
2000 1
2015 1
2020 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. Brose MS, et al. Among authors: binder ta. J Clin Endocrinol Metab. 2022 Feb 17;107(3):776-787. doi: 10.1210/clinem/dgab731. J Clin Endocrinol Metab. 2022. PMID: 34664662 Free PMC article. Clinical Trial.
Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Taylor MH, et al. Among authors: binder ta. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. Cancer Med. 2023. PMID: 36464853 Free PMC article. Clinical Trial.
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Pal SK, Puente J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Ciuleanu T, Lee JL, Sunela K, O'Hara K, Binder TA, Peng L, Smith AD, Rha SY. Pal SK, et al. Among authors: binder ta. Eur Urol. 2022 Sep;82(3):283-292. doi: 10.1016/j.eururo.2021.12.024. Epub 2022 Feb 21. Eur Urol. 2022. PMID: 35210132 Free article. Clinical Trial.
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers.
Hong DS, Parikh A, Shapiro GI, Varga A, Naing A, Meric-Bernstam F, Ataman Ö, Reyderman L, Binder TA, Ren M, Liu M, Dayal S, Siu AY, Sachdev P, Xu L, Bhagawati-Prasad V, Tchakov I, Ooi CE, Bao X, Marabelle A. Hong DS, et al. Among authors: binder ta. J Immunother Cancer. 2020 Jun;8(1):e000222. doi: 10.1136/jitc-2019-000222. J Immunother Cancer. 2020. PMID: 32554609 Free PMC article. Clinical Trial.
Gingival fluid levels of acid and alkaline phosphatase.
Binder TA, Goodson JM, Socransky SS. Binder TA, et al. J Periodontal Res. 1987 Jan;22(1):14-9. doi: 10.1111/j.1600-0765.1987.tb01534.x. J Periodontal Res. 1987. PMID: 2950223 No abstract available.
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA. Twelves C, et al. Among authors: binder ta. Breast Cancer Res. 2015 Dec 9;17(1):150. doi: 10.1186/s13058-015-0657-1. Breast Cancer Res. 2015. PMID: 27391598 Free PMC article. Clinical Trial.